Clinical Trial Update: GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial (GZ17-6.02) for advanced castration-resistant prostate cancer is currently recruiting after progression on anti-androgen therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• GZ17-6.02

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Castration-resistant Prostate Cancer | Phase 1 | Status: RECRUITING